Crestor | Rosuvastatin Calcium Tablet Breastfeeding
For most of the drugs advantages of taking medications overweighs the potential risks however some drugs could be really dangerous for breastfed baby hence every medication shall be considered separately. In this page we will discuss about purpose of Crestor | Rosuvastatin Calcium Tablet and its risk associated with lactation. We will also discuss the usage of Crestor | Rosuvastatin Calcium Tablet and some common side effects associated with Crestor | Rosuvastatin Calcium Tablet.

What is Crestor | Rosuvastatin Calcium Tablet used for?


CRESTOR is an HMG Co‑A reductase inhibitor indicated for: •patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total‑C, LDL‑C, ApoB, nonHDL‑C, and TG levels and to increase HDL‑C (1.1) •patients with hypertriglyceridemia as an adjunct to diet (1.2) •patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet (1.3) •patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL‑C, total-C, and ApoB (1.4) •slowing the progression of atherosclerosis as part of a treatment strategy to lower total‑C and LDL‑C as an adjunct to diet (1.5) •pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total‑C, LDL‑C and ApoB after failing an adequate trial of diet therapy (1.1) •risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors (1.6) Limitations of use (1.7): •CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL‑C, and triglycerides and to increase HDL‑C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. Pediatric Patients 10 to 17 years of age with Heterozygous Familial Hypercholesterolemia (HeFH) Adjunct to diet to reduce Total‑C, LDL‑C and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 10‑17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL‑C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL‑C, Total‑C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total‑C and LDL‑C to target levels. 1.6 Primary Prevention of Cardiovascular Disease In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age ≥ 50 years old in men and ≥ 60 years old in women, hsCRP ≥ 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL‑C, smoking, or a family history of premature coronary heart disease, CRESTOR is indicated to: •reduce the risk of stroke •reduce the risk of myocardial infarction •reduce the risk of arterial revascularization procedures 1.7 Limitations of Use CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias.

What are the risk associated with Crestor | Rosuvastatin Calcium Tablet usage while breastfeeding? What precautions shall I take while using it in breastfeeding?

Crestor | Rosuvastatin Calcium Tablet high risk while breastfeeding
As Crestor | Rosuvastatin Calcium Tablet is made of only Rosuvastatin, and Rosuvastatin is unsafe to use in breastfeeding we can safely reach on conclusion that Crestor | Rosuvastatin Calcium Tablet is also unsafe to use while breastfeeding. Below is detailed analysis of Rosuvastatin and Crestor | Rosuvastatin Calcium Tablet during location. We recommend you to go through provided detailed analysis as below take decision accordingly. We also recommend you talk to your health care provider before making final decision.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers It is not known whether rosuvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. In rats, breast milk concentrations of rosuvastatin are three times higher than plasma levels; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because HMG‑CoA reductase inhibitors have a potential to cause serious adverse reactions in nursing infants, women who require CRESTOR treatment should be advised not to nurse their infants [see Contraindications (4) ].

Crestor | Rosuvastatin Calcium Tablet Breastfeeding Analsys


Rosuvastatin while Breastfeeding

Unsafe

CAS Number: 147098-20-2

Statin pharmacologically acts by inhibiting cholesterol synthesis. Excretion into breast milk is non-significant. Its low oral biodisponibility makes absorption by the infant unlikely. Influence on alteration of breast milk fat composition is unknown. High amount of cholesterol is required by the infant to ensure appropriate development of nervous system, cell membranes and hormones or vitamin production. Avoiding use while exclusive breastfeeding would be advisable. Atorvastatin is probably safer because of a higher molecular weight that would interfer with excretion into breast milk. Pravastatin has also shown a low excretion. Simvastatin has the lowest oral biodisponibility. Interruption of drug hypercholesterolemia treatment while breastfeeding would probably not affect long-term outcome of the disease. A hypolipidemic diet should be followed.


Crestor | Rosuvastatin Calcium Tablet Breastfeeding Analsys - 2


Rosuvastatin while Breastfeeding

CAS Number: 287714-41-4

Is Crestor | Rosuvastatin Calcium Tablet safe while breastfeeding

Levels of rosuvastatin in milk are low, but no relevant published information exists with its use during breastfeeding. The consensus opinion is that women taking a statin should not breastfeed because of a concern with disruption of infant lipid metabolism. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.


Crestor | Rosuvastatin Calcium Tablet safe for breastfeeding

What should I do if I am breastfeeding mother and I am already exposed to Crestor | Rosuvastatin Calcium Tablet?

We have already established that Crestor | Rosuvastatin Calcium Tablet is unsafe in breastfeeding and breastfeeding while using Crestor | Rosuvastatin Calcium Tablet is not a good idea however if have already used and then breastfed the baby then you shall monitor the behavior and health of baby closely and inform your doctor as soon as possible. In case of emergency please call 911.


I am nursing mother and my doctor has suggested me to use Crestor | Rosuvastatin Calcium Tablet, is it safe?

If your doctor knows that you are breastfeeding mother and still prescribes Crestor | Rosuvastatin Calcium Tablet then there must be good reason for that as Crestor | Rosuvastatin Calcium Tablet is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using Crestor | Rosuvastatin Calcium Tablet, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using Crestor | Rosuvastatin Calcium Tablet and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of Crestor | Rosuvastatin Calcium Tablet in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week